Treatments for idiopathic pulmonary fibrosis: Dr. Richeldi replies

New England Journal of Medicine

Volumn 371, Issue 8, 2014, Pages 783-

  Richeldi, Luca ^a  

^a National Institute for Health Research Respiratory Biomedical Research Unit ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; NOTE;

ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; PROTEIN KINASE INHIBITORS;

EID: 84906911100     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1407776     Document Type: Letter

References (2)

1. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
2. Food and Drug Administration briefing information for the March 9, 2010 meeting of the Pulmonary-Allergy Drugs Advisory Committee (http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugs AdvisoryCommittee/ucm203079.htm).